Australian and New Zealand Intensive Care Society Clinical Trials Group   Report issue

Academic/Hospital Phase 3 Phase 4
Founded: Melbourne Australia (1994)

Organization Overview

First Clinical Trial
2005
NCT00220987
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Australian and New Zealand Intensive Care Society Clinical Trials Group

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Brain Injuries (Phase 3)

Brain Injuries, Traumatic (Phase 3)

Critical Illness (Phase 3)

Gastrointestinal Hemorrhage (Phase 3)

Hemorrhage (Phase 3)

Hypovolemia (Phase 4)

Shock (Phase 4)

Shock, Septic (Phase 4)

Thromboembolism (Phase 3)

Thrombosis (Phase 3)

Venous Thrombosis (Phase 3)

Wounds and Injuries (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 9
  • # of Trial APIs: 11